Generated by AI
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical need. Aurinia Pharmaceuticals develops and commercializes LUPKYNIS, an oral treatment for adults with active lupus nephritis, a serious kidney complication associated with systemic lupus erythematosus. The company also advances pipeline programs such as aritinercept, a dual inhibitor targeting B cell-activating factor and proliferation-inducing ligand for potential autoimmune indications. Aurinia Pharmaceuticals serves patients and healthcare providers in markets including the United States and Japan, with its commercial and research activities centered on immune-mediated disease treatment. Based in Edmonton, Canada, the company operates as a specialist player in the autoimmune disease segment of the biopharmaceutical industry.
Website#140, 14315 – 118 Avenue
Edmonton, AB, T5L 4S6
Canada
The latest articles about AUPH.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Jul 28's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Investors talking about AUPH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.